{"url_path":"/sec/cpix/8-k/2026-07-01/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 ****Termination of a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001104659-26-079871-index.html","accession_number":"0001104659-26-079871","cik":"0001087294","ticker":"CPIX","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001104659-26-079871-index.html","primary_entity_key":"0001087294","primary_entity_name":"CUMBERLAND PHARMACEUTICALS INC"},"word_count":151,"has_tables":true,"body_markdown":"** **\n\n**Item 1.02****Termination of a Material Definitive Agreement.**\n\n \n\nOn June 29, 2026, in connection with the closing\nof the Transaction, Cumberland terminated and repaid in full all outstanding obligations (approximately $5.3 million) due under that certain\nRevolving Credit Loan Agreement, dated as of September 5, 2023, by and between Pinnacle Bank and the Company (as amended, the “**Loan\nAgreement**”). In connection with the termination and repayment in full of all outstanding obligations under the Loan Agreement,\nall related liens and security interests were terminated, discharged and released.\n\n \n\nThe Loan Agreement is more fully described in the\nCompany’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “**SEC**”) on\nMay 8, 2026, which description is incorporated herein by reference. The description of the Loan Agreement incorporated by reference is\nnot complete and is subject to and entirely qualified by reference to the full text of the Loan Agreement."}